Ernexa Therapeutics (ERNAW) Non-Current Assets (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Non-Current Assets data on file, last reported at $547000.0 in Q1 2026.

• Quarterly Non-Current Assets fell 80.79% year-over-year to $547000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (down 82.9% YoY) and the FY2025 annual result came in at $2.7 million, down 7.4% from the prior year.
• Non-Current Assets retreated to $547000.0 in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $45.2 million in Q3 2023 to a low of $547000.0 in Q1 2026.
• A 5-year average of $15.8 million and a median of $5.1 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets soared 791.15% — and 2025, when it plunged 93.49%.
• Tracing ERNAW's Non-Current Assets over 5 years: stood at $8.6 million in 2022, then surged by 359.79% to $39.5 million in 2023, then slumped by 92.62% to $2.9 million in 2024, then retreated by 7.4% to $2.7 million in 2025, then plunged by 79.75% to $547000.0 in 2026.
• The last three Non-Current Assets figures came in at $547000.0 (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.